Ocugen posts corporate presentation showing positive retinal gene therapy data

Ocugen, Inc.

Mean change in total atrophy area: treated 0.12±0.36 mm2 vs untreated 0.73±0.26 mm2 (84% less progression).
LL VA decline at 6 months was lower in treated eyes compared to untreated across multiple study cohorts.
Presentation features data from cohorts 006-001, 007-001, and 006-004 suggesting consistent treatment benefit.
Ocugen plans to use this presentation in discussions with investors and analysts on January 29, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.